Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats.

Therapeutic monoclonal antibodies (mAbs) have heterogeneities in their structures. Multiple studies have reported that the variety of post-translational modifications could affect the pharmacokinetic profiles or pharmacological potencies of therapeutic mAbs. Taking into the account that the structur...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuki Otani, Atushi Yonezawa, Masahiro Tsuda, Satoshi Imai, Yasuaki Ikemi, Shunsaku Nakagawa, Tomohiro Omura, Takayuki Nakagawa, Ikuko Yano, Kazuo Matsubara
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0169588&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850230079324422144
author Yuki Otani
Atushi Yonezawa
Masahiro Tsuda
Satoshi Imai
Yasuaki Ikemi
Shunsaku Nakagawa
Tomohiro Omura
Takayuki Nakagawa
Ikuko Yano
Kazuo Matsubara
author_facet Yuki Otani
Atushi Yonezawa
Masahiro Tsuda
Satoshi Imai
Yasuaki Ikemi
Shunsaku Nakagawa
Tomohiro Omura
Takayuki Nakagawa
Ikuko Yano
Kazuo Matsubara
author_sort Yuki Otani
collection DOAJ
description Therapeutic monoclonal antibodies (mAbs) have heterogeneities in their structures. Multiple studies have reported that the variety of post-translational modifications could affect the pharmacokinetic profiles or pharmacological potencies of therapeutic mAbs. Taking into the account that the structural modification of mAbs would affect the efficacy, it is worth investigating the structural alteration of therapeutic mAbs in the blood and the relationship between their structures and pharmacological effects. Herein, we have developed the method to isolate rituximab from plasma in which endogenous IgGs interfere the detection of rituximab, and successfully developed the analytical method with a liquid chromatograph time-of-flight mass spectrometer to detect the structure of rituximab in plasma with errors less than 30 parts per millions. Eight types of carbohydrate chains in rituximab were detected by this method. Interestingly, time-dependent changes in carbohydrate chains such as AAF (G2F) and GnGn (G0) were observed in rats, although the amino acids were stable. Additionally, these structural changes were observed via incubation in plasma as in the rat experiment, suggesting that a certain type of enzyme in plasma caused the alterations of the carbohydrate chains. The present analytical methods could clarify the actual pharmacokinetics of therapeutic mAbs, and help to evaluate the interindividual variations in pharmacokinetics and efficacy.
format Article
id doaj-art-e2bc225ef0734b0db6beb0aeb68cfbba
institution OA Journals
issn 1932-6203
language English
publishDate 2017-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-e2bc225ef0734b0db6beb0aeb68cfbba2025-08-20T02:03:58ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01121e016958810.1371/journal.pone.0169588Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats.Yuki OtaniAtushi YonezawaMasahiro TsudaSatoshi ImaiYasuaki IkemiShunsaku NakagawaTomohiro OmuraTakayuki NakagawaIkuko YanoKazuo MatsubaraTherapeutic monoclonal antibodies (mAbs) have heterogeneities in their structures. Multiple studies have reported that the variety of post-translational modifications could affect the pharmacokinetic profiles or pharmacological potencies of therapeutic mAbs. Taking into the account that the structural modification of mAbs would affect the efficacy, it is worth investigating the structural alteration of therapeutic mAbs in the blood and the relationship between their structures and pharmacological effects. Herein, we have developed the method to isolate rituximab from plasma in which endogenous IgGs interfere the detection of rituximab, and successfully developed the analytical method with a liquid chromatograph time-of-flight mass spectrometer to detect the structure of rituximab in plasma with errors less than 30 parts per millions. Eight types of carbohydrate chains in rituximab were detected by this method. Interestingly, time-dependent changes in carbohydrate chains such as AAF (G2F) and GnGn (G0) were observed in rats, although the amino acids were stable. Additionally, these structural changes were observed via incubation in plasma as in the rat experiment, suggesting that a certain type of enzyme in plasma caused the alterations of the carbohydrate chains. The present analytical methods could clarify the actual pharmacokinetics of therapeutic mAbs, and help to evaluate the interindividual variations in pharmacokinetics and efficacy.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0169588&type=printable
spellingShingle Yuki Otani
Atushi Yonezawa
Masahiro Tsuda
Satoshi Imai
Yasuaki Ikemi
Shunsaku Nakagawa
Tomohiro Omura
Takayuki Nakagawa
Ikuko Yano
Kazuo Matsubara
Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats.
PLoS ONE
title Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats.
title_full Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats.
title_fullStr Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats.
title_full_unstemmed Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats.
title_short Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats.
title_sort time dependent structural alteration of rituximab analyzed by lc tof ms after a systemic administration to rats
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0169588&type=printable
work_keys_str_mv AT yukiotani timedependentstructuralalterationofrituximabanalyzedbylctofmsafterasystemicadministrationtorats
AT atushiyonezawa timedependentstructuralalterationofrituximabanalyzedbylctofmsafterasystemicadministrationtorats
AT masahirotsuda timedependentstructuralalterationofrituximabanalyzedbylctofmsafterasystemicadministrationtorats
AT satoshiimai timedependentstructuralalterationofrituximabanalyzedbylctofmsafterasystemicadministrationtorats
AT yasuakiikemi timedependentstructuralalterationofrituximabanalyzedbylctofmsafterasystemicadministrationtorats
AT shunsakunakagawa timedependentstructuralalterationofrituximabanalyzedbylctofmsafterasystemicadministrationtorats
AT tomohiroomura timedependentstructuralalterationofrituximabanalyzedbylctofmsafterasystemicadministrationtorats
AT takayukinakagawa timedependentstructuralalterationofrituximabanalyzedbylctofmsafterasystemicadministrationtorats
AT ikukoyano timedependentstructuralalterationofrituximabanalyzedbylctofmsafterasystemicadministrationtorats
AT kazuomatsubara timedependentstructuralalterationofrituximabanalyzedbylctofmsafterasystemicadministrationtorats